Angiogenesis modulation in cancer research: Novel clinical approaches

Nature Reviews Drug Discovery

Volumn 1, Issue 6, 2002, Pages 415-426

  Cristofanilli, Massimo ^a   Charnsangavej, Chusilp ^a   Hortobagyi, Gabriel N ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 4 DEDIMETHYLAMINOSANCYCLINE; 5 AMINO 1 [3,5 DICHLORO 4 (4 CHLOROBENZOYL)BENZYL] 1H 1,2,3 TRIAZOLE 4 CARBOXAMIDE; AE 941; ANGIOGENESIS INHIBITOR; ANGIOSTATIN; ANGIOZYME; ANTINEOPLASTIC AGENT; BASIC FIBROBLAST GROWTH FACTOR; BEVACIZUMAB; CETUXIMAB; CYTOTOXIC AGENT; ENDOSTATIN; ERLOTINIB; GEFITINIB; IMATINIB; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY LM 609; PLASMIN INHIBITOR; PLASMINOGEN ACTIVATOR INHIBITOR; PLATELET DERIVED GROWTH FACTOR; PROTEIN TYROSINE KINASE INHIBITOR; REBIMASTAT; SEMAXANIB; TANOMASTAT; TRASTUZUMAB; UNINDEXED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; BLEEDING DISORDER; BONE PAIN; CANCER CHEMOTHERAPY; CANCER RESEARCH; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MONITORING; ECHOGRAPHY; HEADACHE; HUMAN; IMAGING SYSTEM; KAPOSI SARCOMA; KIDNEY CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; METASTASIS; MODULATION; MYALGIA; NAUSEA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SOLID TUMOR; TUMOR GROWTH; VOMITING; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); VASCULARIZATION;

ANGIOGENESIS INHIBITORS; CLINICAL TRIALS; HUMANS; MAGNETIC RESONANCE IMAGING; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; TOMOGRAPHY, X-RAY COMPUTED;

EID: 0036593385     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd819     Document Type: Review

References (87)

1. Carmeliet, P. Mechanisms of angiogenesis and arteriogenesis. Nature Med. 6, 389-395 (2000).
2. Folkman, J. Tumour angiogenesis: therapeutic implications. N. Engl. J. Med. 285, 1182-1186 (1971).
3. Skobe, M. et al. Halting angiogenesis suppresses carcinoma cell invasion. Nature Med. 3, 1222-1227 (1997).
4. Zhang, H. T. et al. Enhancement of tumour growth and vascular density by transfection of vascular endothelial cell growth factor into MCF-7 human breast carcinoma cells. J. Natl Cancer Inst. 87, 213-219 (1995).
5. Carmeliet, P. & Jain, R. K. Angiogenesis in cancer and other diseases. Nature 407, 249-257 (2001).
6. Yancopoulos, G. D. et al. Vascular-specific growth factors and blood vessel formation. Nature 407, 242-248 (2000).
7. Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57-70 (2000).
8. Bouck, N., Stellmach, V. & Hsu, S. C. How tumours become angiogenic. Adv. Cancer Res. 69, 135-174 (1996).
9. Robinson, C. J. et al. The splice variants of vascular endothelial growth factor (VEGF) and their receptors. J. Cell Sci. 114, 853-865 (2001).
10. Hiraoka, N. et al. Matrix metalloproteinases regulate neovascularization by acting as pericellular fibrinolysins. Cell 91, 365-377 (1998).
11. Levine, H. A. et al. A mathematical model for the roles of pericytes and macrophages in the initiation of angiogenesis. The role of protease inhibitors in preventing angiogenesis. Mathem. Biosc. 168, 77-115 (2000).
12. Sturzebecher, J. et al. 3-Amidinophenylalanine-based inhibitors of urokinase. Bioorg. Med. Chem. Lett. 9, 3147-3152 (1999).
13. Presta, L. G. et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumours and other disorders. Cancer Res. 57, 4593-4599 (1997).
14. Shaheen, R. M. et al. Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumour and endothelial cell apoptosis. Cancer Res. 59, 5412-5416 (1999).
15. Oshika, Y. et al. Ribozyme approach to downregulate vascular endothelial growth factor (VEGF) 189 expression in non-small cell lung cancer (NSCLC). Eur. J. Cancer 36, 2390-2396 (2000).
16. Westphal, J. R. et al. Angiostatin generation by human tumour cell lines: involvement of plasminogen activators. Int. J. Cancer 86, 760-767 (2000).
17. Huang, X. et al. Soluble recombinant endostatin purified from Escherichia coli: antiangiogenic activity and antitumour effect. Cancer Res. 61, 478-481 (2001).
18. Fotsis, T. et al. The endogenous oestrogen metabolite 2-methoxyestradiol inhibits angiogenesis and suppresses tumour growth. Nature 368, 237-239 (1994).
19. Pasqualini, R. et al. Aminopeptidase N is a receptor for tumour-homing peptides and a target for inhibiting angiogenesis. Cancer Res. 60, 722-727 (2000).
20. v-Integrin, p38 mitogen-activated protein kinase, and urokinase plasminogen activator are functionally linked in invasive breast cancer cells. J. Biol. Chem. 276, 47901-47905 (2001).
21. O-Charoenrat, P., Rhys-Evans, P., Modjtahedi, H. & Eccles, S. A. Vascular endothelial growth factor family members are differentially regulated by c-erbB signaling in head and neck squamous carcinoma cells. Clin. Exp. Metastasis 18, 155-161 (2000).
22. Ciardiello, F. et al. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin. Cancer Res. 7, 1459-1465 (2001).
23. Rak, J. et al. Ras regulation of vascular endothelial growth factor and angiogenesis. Methods Enzymol 333, 267-283 (2001).
24. Ang, Y. et al. Aberrant p53 expression correlates with expression of vascular endothelial growth factor mRNA and interleukin-8 mRNA and neoangiogenesis in non-small cell lung cancer. J. Clin. Oncol. 20, 900-910 (2002).
25. Giatromanolaki, A. et al. Relation of hypoxia inducible factor 1α and 2α in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival. Br. J. Cancer 85, 881-890 (2001).
26. Sunwoo, J. B. et al. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-κB, cell survival, tumour growth, and angiogenesis in squamous cell carcinoma. Clin. Cancer Res. 7, 1419-1429 (2001).
27. Okada, A. et al. Membrane-type matrix metalloproteinase (MT-MMP) gene is expressed in stromal cells of human colon, breast and head and neck carcinoma. Proc. Natl Acad. Sci. USA 92, 2730-2734 (1995).
28. Dewhrist, M. W. et al. Morphologic and hemodynamic comparison of tumour and healing normal tissue microvasculature. Int. J. Radiat. Oncol. Biol. Phys. 17, 91-99 (1989).
29. Lal, B. K., Varma, S., Pappas, P. J., Hobson, R. W. & Duran, W. N. VEGF increases permeability of the endothelial cell by activation of PKB/Akt, endothelial cell nitric-oxide synthase, and MAP kinase pathways. Microvasc. Res. 62, 252-262 (2001).
30. 2 gradients in solid tumours in vivo: simultaneous high-resolution measurements reveal a lack of correlation. Nature Med. 3, 177-182 (1997).
31. Graeber, T. G. et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 379, 88-91 (1996).
32. Li, W. W. Tumour angiogenesis: molecular pathology, therapeutic targeting, and imaging. Acad. Radiol. 7, 800-811 (2000).
33. Stohrer, M., Boucher, Y., Stangassinger, M. & Jain, R. K. Oncotic pressure in solid tumours is elevated. Cancer Res. 60, 4251-4255 (2000).
34. Hansen-Algenstaedt, N. et al. Tumour oxygenation in hormone-dependent tumours during vascular endothelial growth factor receptor-2 blockade, hormone ablation, and chemotherapy. Cancer Res. 60, 4556-4560 (2000).
35. Abramovitch, R., Dafni, H., Smouha, E., Benjamin, L. E. & Neeman, M. In vivo prediction of vascular susceptibility to endothelial growth factor withdrawal: magnetic resonance imaging of C6 rat glioma in nude mice. Cancer Res. 59, 5012-5016 (1999).
36. Pham, C. D. et al. Magnetic resonance imaging detects suppression of tumour vascular permeability after administration of antibody to vascular endothelial growth factor. Cancer Invest. 16, 225-230 (1998).
37. Taylor, N. J. et al. BOLD MRI of human tumour oxygenation during carbogen breathing. J. Magn. Reson. Imaging 14, 156-163 (2001).
38. Van Dijke C. F. et al. Mammary carcinoma model: correlation of macromolecular contrast-enhanced MR imaging characterizations of tumour microvasculature and histologic capillary density. Radiology 198, 813-818 (1996).
39. Port, R. E. et al. Multicompartment analysis of gadolinium chelate kinetics: blood-tissue exchange in mammary tumours as monitored by dynamic MR imaging. J. Magn. Reson. Imaging 10, 233-241 (1999).
40. Tofts, P. S. et al. Quantitative analysis of dynamic Gd-DTPA enhancement in breast tumours using a permeability model. Magn. Reson. Med. 33, 564-568 (1995).
41. Brasch, R. C et al. In vivo monitoring of tumour angiogenesis with MR imaging. Acad. Radiol. 7, 812-823 (2000).
42. Jacquemier, J. et al. Angiogenesis as a prognostic marker in breast carcinoma with conventional adjuvant chemotherapy: a multiparametric and immunohistochemical analysis. J. Pathol. 184, 130-135 (1998).
43. Linderholm, B. et al. Vascular endothelial growth factor is of high prognostic value in node-negative breast carcinoma J. Clin. Oncol. 16, 3121-3128 (1998).
44. Fuss, M. et al. Tumour angiogenesis of low-grade astrocytomas measured by dynamic susceptibility contrast-enhanced MRI (DSC-MRI) is predictive of local tumour control after radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 51, 478-482 (2001).
45. Padhani, A. R. et al. Effects of androgen deprivation on prostatic morphology and vascular permeability evaluated with MR imaging. Radiology 218, 365-374 (2001).
46. Brasch, R. et al. Assessing tumour angiogenesis using macromolecular MR imaging contrast media. J. Magn. Reson. Imaging 7, 68-74 (1997).
47. Ferrara, K. W. et al. Evaluation of tumour angiogenesis with US: imaging, Doppler, and contrast agents. Acad. Radiol. 7, 824-839 (2000).
48. Fleischer, A. C. Sonographic depiction of tumour vascularity and flow: from in vivo models to clinical applications. J. Ultrasound Med. 11, 377-385 (1992).
49. Ismail, M., Peterson, R. O., Alexander A. A., Newschaffer, C. & Gomella, L. G. Color Doppler imaging in predicting the biologic behavior of prostate cancer: correlation with disease-free survival. Urology 50, 906-912 (1997).
50. Lee, W. J. et al. Breast cancer vascularity: color Doppler sonography and histopathology study. Breast Cancer Res. Treat 37, 291-298 (1996).
51. Donnelly, E. F., Geng, L., Wojcicki, W. E., Fleischer, A. C. & Hallahan, D. E. Quantified power Doppler US of tumour blood flow correlates with microscopic quantification of tumour blood vessels. Radiology 219, 166-170 (2001).
52. Rooks, V., Beecken, W.-D., Iordanescu, I. & Taylor, G. A. Sonographic evaluation of orthotopic bladder tumours in mice treated with TNP-470, an angiogenic inhibitor. Acad. Radiol. 8, 121-127 (2001).
53. Blankenberg, F. G. et al. Role of radionuclide imaging in trials of antiangiogenic therapy. Acad. Radiol. 7, 851-867 (2000).
54. Haubner, R. et al. Glycosylated RGD-containing peptides: tracer for tumour targeting and angiogenesis imaging with improved biokinetics. J. Nucl. Med. 42, 326-336 (2001).
55. Miles, K. A. Tumour angiogenesis and its relation to contrast enhancement on computerised tomography: a review. Eur. J. Radiol. 30, 198-205 (1999).
56. Blomley, M. J. K. & Dawson, P. Bolus dynamics: theoretical and experimental aspects. Br. J. Radiol. 70, 351-359 (1997).
57. Cenic, A., Nabavi, D. G., Craen, R. A., Gelb, A. W. & Lee, T. Y. A CT method to measure hemodynamics in brain tumours: validation and application to cerebral blood flow maps. Am. J. Neuroradiol. 21, 462-470 (2000).
58. Shaheen, R. M. et al. Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumour and endothelial cell apoptosis. Cancer Res. 59, 5412-5416 (1999).
59. Solorzano, C. C. et al. In vivo intracellular signaling as a marker of antiangiogenic activity. Cancer Res. 61, 7048-7051 (2001).
60. Monestiroli, S. et al. Kinetics and viability of circulating endothelial cells as surrogate angiogenesis marker in an animal model of human lymphoma. Cancer Res. 61, 4341-4344 (2001).
61. Poon, R. T.-P., Fan, S. -T. & Wang, J. Clinical implications of circulating angiogenic factors in cancer patients. J. Clin. Oncol. 19, 1207-1225 (2001).
62. Millauer, B. et al. High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell 72, 835-846 (1993).
63. Millauer B et al. Dominant-negative inhibition of Flk-1 suppresses the growth of many tumour types in vivo. Cancer Res. 56, 1615-1620 (1996).
64. Rosen, L. S. et al. Phase I dose-escalating trial of SU5416, a novel angiogenesis inhibitor in patients with advanced malignancies. Proc. Am. Soc. Clin. Oncol. 18, 618 (1999).
65. Gordon, et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J. Clin. Oncol. 19, 843-850 (2001).
66. Margolin, K. et al. Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. J. Clin. Oncol. 19, 851-856 (2001).
67. Rowinsky, E. K. et al. Phase I pharmacologic study of the specific metalloproteinase inhibitor BAY 12-9566 on a protacted oral daily dosing schedule in patients with solid malignancies. J. Clin. Oncol. 18, 178-186 (2000).
68. 3. Clin. Cancer Res. 6, 3056-3061 (2000).
69. Boehle, A. S. et al. Human endostatin inhibits growth of human non-small cell lung cancer in a murine xenotransplant model. Int. J. Cancer 94, 420-428 (2001).
70. Fogler, W. E. et al. Recombinant human endostatin demonstrates consistent and predictable pharmacokinetics following intravenous bolus administration to cancer patients. Proc. Am. Soc. Clin. Oncol. 20, 274 (2001).
71. Eder, J. P. et al. A Phase I pharmacokinetic and pharmacodynamic trial of recombinant human endostatin. Proc. Am. Soc. Clin. Oncol. 20, 275 (2001).
72. Thomas, J. P. et al. A Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin. Proc. Am. Soc. Clin. Oncol. 20, 276 (2001).
73. Herbst, R. S. et al. Phase I clinical trial of recombinant human endostatin (rHE) in patients (Pts) with solid tumours: pharmacokinetic (PK), safety and efficacy analysis using surrogate endpoints of tissue and radiologic response. Proc. Am. Soc. Clin. Oncol. 20, 9 (2001).
74. Davis, D. W. et al. Quantitative analysis of tumour vascular targeting: effects of endostatin in a Phase I clinical trial. J. Clin. Cancer Res. 7 (Suppl.), 3711 (2001).
75. Soker, S. et al. Circulating endothelial progenitor cells in cancer diagnosis and therapy. J. Clin. Cancer Res. 7 (Suppl.), 3665 (2001).
76. Therasse, P. et al. New guidelines to evaluate the response to treatment in solid tumours. J. Natl Cancer Inst. 92, 205-216 (2000).
77. Kopec, J. A., Abramowicz, M. & Esdail, J. M. Randomized discontinuation trials: utility and efficiency. J. Clin. Epidemiol. 46, 959-971 (1993).
78. Thall, P. F., Simon, R. M. & Estey E. H. Bayesian sequential monitoring designs for single-arm trials with multiple outcomes. Stat. Med. 14, 357-379 (1995).
79. Ratain, M. J. et al. Clinical trial designs for cytotoxic agents J. Clin. Oncol. 19, 3154-3155 (2000).
80. Rosner, G. L., Stadley, W. & Ratain, M. J. The randomized discontinuation design: application to cytotoxic antineoplastic agents. J. Clin. Oncol. (in the press).
81. Kohn, E. C. et al. Structure-function analysis and growth inhibition by carboxyamido-triazole, CAI. Cancer Res. 54, 935-942 (1994).
82. Bonomi, P. Matrix metalloproteinases and matrix metalloproteinase inhibitors in lung cancer. Semin. Oncol. 29, 78-86 (2002).
83. Coussens, L. M., Fingleton, B. & Matrisian, L. M. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 295, 2388-2392 (2002).
84. Khokha, R. Suppression of the tumorigenic and metastatic abilities of murine B16-F10 melanoma cells in vivo by the overexpression of the tissue inhibitor of metalloproteinases-1. J. Natl Cancer Inst. 86, 299-304 (1994).
85. Gehan, E. A. & Freireich, E. J. Non-randomized controls in cancer clinical trials. N. Engl. J. Med. 290, 198-203 (1974).
86. Simon, R. Optimal two-stage designs for Phase II clinical trials. Control Clin. Trials 10, 1-10 (1989).
87. Green, S. & Weiss, G. R. Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest. New Drugs 10, 239-253 (1992).